MX374276B - Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). - Google Patents
Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).Info
- Publication number
- MX374276B MX374276B MX2016010838A MX2016010838A MX374276B MX 374276 B MX374276 B MX 374276B MX 2016010838 A MX2016010838 A MX 2016010838A MX 2016010838 A MX2016010838 A MX 2016010838A MX 374276 B MX374276 B MX 374276B
- Authority
- MX
- Mexico
- Prior art keywords
- pcsk9
- vaccines
- proprotein convertase
- convertase subtilisin
- kexin type
- Prior art date
Links
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 title 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157221 | 2014-02-28 | ||
| PCT/EP2015/053725 WO2015128287A1 (en) | 2014-02-28 | 2015-02-23 | Pcsk9 vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010838A MX2016010838A (es) | 2016-11-17 |
| MX374276B true MX374276B (es) | 2025-03-06 |
Family
ID=50179534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010838A MX374276B (es) | 2014-02-28 | 2015-02-23 | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10004791B2 (enExample) |
| EP (1) | EP3110439B1 (enExample) |
| JP (1) | JP6494667B2 (enExample) |
| KR (1) | KR102360250B1 (enExample) |
| CN (1) | CN106459209B (enExample) |
| AU (1) | AU2015222283B2 (enExample) |
| BR (1) | BR112016019389A8 (enExample) |
| CA (1) | CA2940315C (enExample) |
| DK (1) | DK3110439T3 (enExample) |
| ES (1) | ES2732741T3 (enExample) |
| IL (1) | IL247159B (enExample) |
| MX (1) | MX374276B (enExample) |
| PL (1) | PL3110439T3 (enExample) |
| RU (1) | RU2698971C2 (enExample) |
| SG (1) | SG11201606685XA (enExample) |
| WO (1) | WO2015128287A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108472344A (zh) | 2015-11-03 | 2018-08-31 | 阿费里斯股份公司 | 用于针对人患者中的自身抗原的疫苗接种方法 |
| US20200270365A1 (en) * | 2016-01-05 | 2020-08-27 | Jiangsu Hengrui Medicine Co., Ltd. | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
| CA3058567A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| WO2022147373A1 (en) * | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101512053B1 (ko) * | 2009-09-03 | 2015-04-28 | 화이자 백신스 엘엘씨 | Ｐｃｓｋ９ 백신 |
| CA2777542A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax213 and ax132 pcsk9 antagonists and variants |
| WO2011053759A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
| GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| ES2565757T3 (es) | 2011-09-13 | 2016-04-06 | Affiris Ag | Vacuna de PCSK9 |
| WO2013148284A1 (en) * | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
-
2015
- 2015-02-23 MX MX2016010838A patent/MX374276B/es active IP Right Grant
- 2015-02-23 CA CA2940315A patent/CA2940315C/en active Active
- 2015-02-23 WO PCT/EP2015/053725 patent/WO2015128287A1/en not_active Ceased
- 2015-02-23 EP EP15714770.3A patent/EP3110439B1/en active Active
- 2015-02-23 BR BR112016019389A patent/BR112016019389A8/pt not_active Application Discontinuation
- 2015-02-23 US US15/122,316 patent/US10004791B2/en active Active
- 2015-02-23 SG SG11201606685XA patent/SG11201606685XA/en unknown
- 2015-02-23 CN CN201580015813.0A patent/CN106459209B/zh active Active
- 2015-02-23 JP JP2016571473A patent/JP6494667B2/ja not_active Expired - Fee Related
- 2015-02-23 RU RU2016138365A patent/RU2698971C2/ru active
- 2015-02-23 DK DK15714770.3T patent/DK3110439T3/da active
- 2015-02-23 AU AU2015222283A patent/AU2015222283B2/en not_active Ceased
- 2015-02-23 ES ES15714770T patent/ES2732741T3/es active Active
- 2015-02-23 PL PL15714770T patent/PL3110439T3/pl unknown
- 2015-02-23 KR KR1020167026735A patent/KR102360250B1/ko not_active Expired - Fee Related
-
2016
- 2016-08-08 IL IL247159A patent/IL247159B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016010838A (es) | 2016-11-17 |
| WO2015128287A1 (en) | 2015-09-03 |
| BR112016019389A8 (pt) | 2022-11-08 |
| SG11201606685XA (en) | 2016-09-29 |
| CN106459209A (zh) | 2017-02-22 |
| DK3110439T3 (da) | 2019-05-13 |
| JP2017508006A (ja) | 2017-03-23 |
| ES2732741T3 (es) | 2019-11-25 |
| CN106459209B (zh) | 2019-10-11 |
| CA2940315A1 (en) | 2015-09-03 |
| EP3110439B1 (en) | 2019-03-27 |
| PL3110439T3 (pl) | 2019-09-30 |
| RU2016138365A (ru) | 2018-03-29 |
| NZ722918A (en) | 2022-03-25 |
| KR102360250B1 (ko) | 2022-02-07 |
| AU2015222283B2 (en) | 2019-11-21 |
| KR20160124901A (ko) | 2016-10-28 |
| EP3110439A1 (en) | 2017-01-04 |
| AU2015222283A1 (en) | 2016-09-08 |
| RU2016138365A3 (enExample) | 2018-08-20 |
| JP6494667B2 (ja) | 2019-04-03 |
| BR112016019389A2 (pt) | 2017-10-24 |
| US20170065689A1 (en) | 2017-03-09 |
| IL247159B (en) | 2018-01-31 |
| RU2698971C2 (ru) | 2019-09-02 |
| CA2940315C (en) | 2022-08-23 |
| US10004791B2 (en) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18040758A (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
| MX374276B (es) | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). | |
| MX2020009401A (es) | Ligadores de nucleótidos modificados. | |
| UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
| LT3529360T (lt) | Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį | |
| EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| EA201592215A1 (ru) | Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9) | |
| BR112019004785A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
| DK3212780T3 (da) | Serinprotease | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MX347475B (es) | Anticuerpos para pcsk9 y usos de los mismos. | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| BR112019004783A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| MX2017011194A (es) | Anticuerpos, usos y métodos. | |
| EA201592245A1 (ru) | Устройство для приготовления раствора гидрокарбоната кальция, применимого для реминерализации воды | |
| MX377774B (es) | Formulaciones de proteinas. | |
| EA201892624A1 (ru) | Растения, дающие бессемянные плоды | |
| MX2023003394A (es) | Variantes de proteasa y sus usos. | |
| MX2015015428A (es) | Eliminacion de riesgo de narcolepsia en vacunas contra influenza. | |
| BR112016019390A2 (pt) | proteínas de fusão uti | |
| MX2017005807A (es) | Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |